HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
Óscar Brochado,Isidoro Martínez,Juan Berenguer,Luz Medrano,Juan González-García,María Ángeles Jiménez-Sousa,Ana Carrero,Víctor Hontañón,Jordi Navarro,Josep M Guardiola,Amanda Fernández-Rodríguez,Salvador Resino,GESIDA Study Group,A Carrero,P Miralles,J C López,F Parras,B Padilla,T Aldamiz-Echevarría,F Tejerina,C Díez,L Pérez-Latorre,C Fanciulli,I Gutiérrez,M Ramírez,S Carretero,J M Bellón,J Bermejo,J Berenguer,V Hontañón,J R Arribas,M L Montes,I Bernardino,J F Pascual,F Zamora,J M Peña,F Arnalich,M Díaz,J González-García,P Domingo,J M Guardiola,E Van den Eynde,M Pérez,E Ribera,M Crespo,J L Casado,F Dronda,A Moreno,M J Pérez-Elías,M A Sanfrutos,S Moreno,C Quereda,A Arranz,E Casas,J de Miguel,S Schroeder,J Sanz,I Santos,M J Bustinduy,J A Iribarren,F Rodríguez-Arrondo,M A Von-Wichmann,J Vergas,M J Téllez,D Vinuesa,L Muñoz,J Hernández-Quero,A Ferrer,M J Galindo,L Ortiz,E Ortega,M Montero,M Blanes,S Cuellar,J Lacruz,M Salavert,J López-Aldeguer,G Pérez,G Gaspar,M Yllescas,P Crespo,E Aznar,H Esteban
DOI: https://doi.org/10.1186/s12929-021-00718-6
2021-03-30
Abstract:Objective: To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods: We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results: HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion: HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients.